Aclarion Inc (ACON)

$12.61 +1.30 (11.49%)
Market Cap 203,000.00
Revenue (ttm) 80,000.00
Net Income (ttm) -4.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,137.50%
Debt to Equity Ratio 0.00
Volume 139,500
Avg Vol 250,634
Day's Range N/A - N/A
Shares Out 19,000.00
Stochastic %K 25%
Beta 0.47
Analysts Hold
Price Target $11,711.70

Latest News on ACON

Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California

Apr 2, 2025, 6:00 AM EDT - 17 hours ago

Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California

Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

Mar 31, 2025, 7:00 AM EDT - 2 days ago

Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

Aclarion Provides Shareholder Update

Mar 13, 2025, 9:25 AM EDT - 20 days ago

Aclarion Provides Shareholder Update

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

Mar 6, 2025, 9:35 AM EST - 27 days ago

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

Aclarion Announces First Commercial Agreement with Scripps Health

Mar 3, 2025, 6:00 AM EST - 4 weeks ago

Aclarion Announces First Commercial Agreement with Scripps Health

Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit

Feb 20, 2025, 6:00 AM EST - 5 weeks ago

Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit

Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body

Feb 11, 2025, 7:58 AM EST - 7 weeks ago

Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Feb 6, 2025, 7:23 AM EST - 7 weeks ago

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded

Feb 4, 2025, 7:23 AM EST - 2 months ago

Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

Nov 21, 2024, 8:00 AM EST - 4 months ago

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

Nov 14, 2024, 5:00 PM EST - 4 months ago

Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 10, 2024, 7:00 AM EDT - 6 months ago

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

Sep 27, 2024, 6:57 AM EDT - 6 months ago

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Sep 13, 2024, 8:30 AM EDT - 7 months ago

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Aclarion Provides Corporate Update on Nociscan AI Technology Milestones

Sep 12, 2024, 6:57 AM EDT - 7 months ago

Aclarion Provides Corporate Update on Nociscan AI Technology Milestones

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

Sep 10, 2024, 6:57 AM EDT - 7 months ago

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market

Sep 5, 2024, 6:57 AM EDT - 7 months ago

Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market

Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

Aug 29, 2024, 6:57 AM EDT - 7 months ago

Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans

Aug 21, 2024, 7:57 AM EDT - 8 months ago

Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans

Aclarion to Present at August 20th Virtual Investor Summit Microcap Event

Aug 15, 2024, 9:48 AM EDT - 8 months ago

Aclarion to Present at August 20th Virtual Investor Summit Microcap Event

Aclarion Announces First Commercial Agreement in Michigan

Aug 14, 2024, 8:08 AM EDT - 8 months ago

Aclarion Announces First Commercial Agreement in Michigan

Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK

Aug 13, 2024, 9:07 AM EDT - 8 months ago

Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK

Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

Jul 9, 2024, 7:00 AM EDT - 9 months ago

Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

Jun 26, 2024, 8:30 AM EDT - 10 months ago

Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London

Jun 25, 2024, 8:30 AM EDT - 10 months ago

Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London

Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain

Apr 25, 2024, 9:14 AM EDT - 1 year ago

Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain

Aclarion Announces Closing of $3.0 Million Public Offering

Feb 27, 2024, 3:22 PM EST - 1 year ago

Aclarion Announces Closing of $3.0 Million Public Offering

Aclarion Announces Pricing of $3.0 Million Public Offering

Feb 26, 2024, 9:15 AM EST - 1 year ago

Aclarion Announces Pricing of $3.0 Million Public Offering

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

Feb 5, 2024, 8:00 AM EST - 1 year ago

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

Jan 22, 2024, 8:00 AM EST - 1 year ago

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

Nov 27, 2023, 8:00 AM EST - 1 year ago

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

Nov 6, 2023, 8:00 AM EST - 1 year ago

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver

Oct 25, 2023, 8:30 AM EDT - 1 year ago

Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

Oct 24, 2023, 8:45 AM EDT - 1 year ago

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan

Oct 23, 2023, 7:00 AM EDT - 1 year ago

Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan

Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report

Aug 25, 2023, 4:10 PM EDT - 1 year ago

Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report

Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI

Jun 14, 2023, 11:27 AM EDT - 1 year ago

Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI

Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting

Jun 8, 2023, 7:30 AM EDT - 1 year ago

Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting

Aclarion Announces New Engagement with The London Clinic and London Spine Clinic

May 30, 2023, 7:30 AM EDT - 2 years ago

Aclarion Announces New Engagement with The London Clinic and London Spine Clinic

Aclarion's Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD

May 23, 2023, 7:30 AM EDT - 2 years ago

Aclarion's Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD

Aclarion, Inc. Announces Delayed 10-Q Filing

May 23, 2023, 7:00 AM EDT - 2 years ago

Aclarion, Inc. Announces Delayed 10-Q Filing

Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts

May 19, 2023, 7:30 AM EDT - 2 years ago

Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts

Aclarion to Host Thought Leadership Symposium at SPINEWEEK 2023

Apr 28, 2023, 11:20 AM EDT - 2 years ago

Aclarion to Host Thought Leadership Symposium at SPINEWEEK 2023

Aclarion Announces Alpesh Patel MD MBA as a Key Opinion Leader Physician Advisor

Mar 7, 2023, 9:19 AM EST - 2 years ago

Aclarion Announces Alpesh Patel MD MBA as a Key Opinion Leader Physician Advisor

Aclarion to Present at Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference on February 21st - 24th, 2023

Feb 16, 2023, 7:00 AM EST - 2 years ago

Aclarion to Present at Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference on February 21st - 24th, 2023

Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium

Feb 15, 2023, 7:00 AM EST - 2 years ago

Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium

Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor

Jan 31, 2023, 10:01 AM EST - 2 years ago

Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor

Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor

Jan 17, 2023, 8:29 AM EST - 2 years ago

Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor

Aclarion to Present at the Jan 26th Virtual Investor Summit Microcap Event

Jan 17, 2023, 8:00 AM EST - 2 years ago

Aclarion to Present at the Jan 26th Virtual Investor Summit Microcap Event

Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor

Dec 22, 2022, 10:36 AM EST - 2 years ago

Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor